Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vantia Therapeutic, a developer of novel, small molecule drugs targeting large areas of unmet medical need, has received £4m in a series B financing from Novo and SV Life Sciences, MVM Life Science Partners and other investors of the company.
Subscribe to our email newsletter
The company will use the money for advancing its two preclinical candidates – VA106483 for nocturia and VA111913 – as a treatment for dysmenorrhoea.
The results from Phase II trial of VA111913 in dysmenorrhoea (painful periods) demonstrated resuction in pain levels in patients who received the drug in the trial.
Vantia CEO Andrew Crockett said they believe both these candidates have the potential to be important drugs in patients who currently have limited treatment options.
Vantia chairman Martin Edwards said Vantia has delivered some very encouraging initial clinical results with its lead programmes and they are pleased to continue supporting the company as it moves these novel compounds forward.